Department of Physical Medicine and Rehabilitation , Charité University Hospital Berlin
Berlin, 10117, Germany
NCT Number: NCT00946738
The effect of deep oscillation and biofeedback on Raynaud's phenomenon secondary to systemic sclerosis (SSc) remains to be determined. A prospective randomized controlled pilot study was performed in SSc patients receiving either deep oscillation, biofeedback thrice a week for four weeks or were randomized to the control group.
Looking for future studies?
Notify Me18 year–80 year
All sexes
Interventional
Not applicable
Berlin, 10117, Germany
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Biofeedback training as behaviour treatment was performed thrice weekly for 4 week.
Deep oscillation providing a pulsing electromagnetic field was performed thrice weekly for 4 weeks.
Time frame: 12 weeks
Time frame: 12 weeks
Charite University, Berlin, Germany
Other
A Prospective Randomized Controlled Study Analyzing the Effect of Biofeedback and Deep Oscillation on Raynaud´s Phenomenon Secondary to Systemic Sclerosis
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03058887
Behavior, Cardiovascular Diseases
Sheffield, United Kingdom
View Trial DetailsNCT02050360
Cardiovascular Diseases, Connective Tissue Diseases
Grenoble, France
View Trial DetailsNCT02583789
Cardiovascular Diseases, Embolism and Thrombosis
Boston, Massachusetts, United States
View Trial DetailsNCT02506062
Cardiovascular Diseases, Embolism and Thrombosis
London, Ontario, Canada
View Trial Details